MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jcp-2024-209848

Медицинская библиотека · Journal of clinical pathology · 2025

Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.

Santisteban-Espejo Antonio, Benavides-De la Fuente Cristian, Mangas-Rojas Alipio, Montero-Pavon Pedro, Bernal-Florindo Irene, Aldaco-Puntas Eduardo, Prieto-Conde Isabel, Perez-Requena Jose, Atienza-Cuevas Lidia, Fernández-Valle Maria Del Carmen, Garzón-López Sebastian, Garcia-Rojo Marcial

СтатьяПеревод пока не подготовлен

Аннотация

AIMS: The prognostic impact of B lymphocytes surrounding Hodgkin and Reed Sternberg (HRS) cells in classic Hodgkin lymphoma (cHL) and pathogenic variants in genes associated with apoptosis regulation remains undefined.

METHODS

We have quantified the proportion of B lymphocytes in tumour microenvironment (TME) in 220 diagnostic slides from 110 cHL patients applying computational pathology (CP) and sequenced cases using a targeted panel including 47 genes recurrently mutated in mature B-cell neoplasms. Kaplan-Meier estimators and multivariate Cox regression on overall survival (OS) and progression-free survival (PFS) were assessed following the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines.

RESULTS

The mean percentage of B lymphocytes was 45.1 (SD: 24.8). Genes recurrently affected by nonsynonymous somatic mutations in 25% or more of patients included EP300, NOTCH and ABL1. A lower number of mutations were discovered in Epstein-Barr virus-positive cHL (21.1% vs 78.8%) reinforcing the notion that viral infection could functionally replace the need for genomic aberrations. Classic Hodgkin lymphoma (cHL) patients that jointly presented a reduction in the number of B lymphocytes in TME (<8%) and the absence of mutations in apoptosis-associated genes (ABL1, BIRC3, CASP8 and FAS) presented a lower OS (mean OS: 31.5 months, 95% CI: 0 to 69.7 months) in comparison with patients without this event (mean OS: 84.7 months, 95% CI: 61.9 to 107.5 months) (p=0.01). This high-risk cHL subgroup also presented a significantly lower PFS (mean PFS: 8.5 months, 95% CI: 7.5 to 9.5 months) in comparison with B-cell-enriched or apoptosis-mutated cHL (mean PFS: 55.2 months; 95% CI: 42.4 to 68 months) (p<0.001).

CONCLUSIONS

This study expands previous data on the value of CP in cHL, and specifically, the distribution of B cells, identifying patients with an increased risk of treatment failure and progression. Furthermore, immune escape by apoptosis dysregulation during clonal selection occurring in germinal centres constitutes a landmark of cHL. These results could be the basis for further development of targeted therapies directed against apoptosis modulators in cHL.

Для цитирования: Santisteban-Espejo Antonio, Benavides-De la Fuente Cristian, Mangas-Rojas Alipio, Montero-Pavon Pedro, Bernal-Florindo Irene, Aldaco-Puntas Eduardo, Prieto-Conde Isabel, Perez-Requena Jose, Atienza-Cuevas Lidia, Fernández-Valle Maria Del Carmen, Garzón-López Sebastian, Garcia-Rojo Marcial. Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.. Journal of clinical pathology. 2025. DOI: 10.1136/jcp-2024-209848.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.